- Markets
- Healthcare
- ADVIKLA
ADVIKLA
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
This data is currently unavailable for this company.
Events:
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does MPS Pharmaa do?
Advik Laboratories Ltd is focused on achieving USFDA standards in pharmaceuticals. Their product range covers ethical, generic, and over the counter drugs in multiple therapeutic categories.
Who are the competitors of MPS Pharmaa?
MPS Pharmaa major competitors are Adline Chem Lab, Fabino Enterprises, Shamrock Indl. Co, Ganga Pharma., Kobo Biotech, Zyden Gentec, Senbo Industries. Market Cap of MPS Pharmaa is ₹6 Crs. While the median market cap of its peers are ₹6 Crs.
Is MPS Pharmaa financially stable compared to its competitors?
MPS Pharmaa seems to be less financially stable compared to its competitors. Altman Z score of MPS Pharmaa is 0 and is ranked 4 out of its 8 competitors.
Does MPS Pharmaa pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. MPS Pharmaa latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has MPS Pharmaa allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is MPS Pharmaa balance sheet?
MPS Pharmaa balance sheet is weak and might have solvency issues
Is the profitablity of MPS Pharmaa improving?
The profit is oscillating. The profit of MPS Pharmaa is -₹0.83 Crs for Mar 2024, -₹1.05 Crs for Mar 2023 and -₹0.14 Crs for Mar 2022
Is the debt of MPS Pharmaa increasing or decreasing?
Yes, The debt of MPS Pharmaa is increasing. Latest debt of MPS Pharmaa is ₹7.43 Crs as of Sep-24. This is greater than Mar-24 when it was ₹7.26 Crs.
Is MPS Pharmaa stock expensive?
There is insufficient historical data to gauge this. Latest PE of MPS Pharmaa is 0
Has the share price of MPS Pharmaa grown faster than its competition?
MPS Pharmaa has given better returns compared to its competitors. MPS Pharmaa has grown at ~29.65% over the last 3yrs while peers have grown at a median rate of 0.0%
Is the promoter bullish about MPS Pharmaa?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in MPS Pharmaa is 35.89% and last quarter promoter holding is 35.89%.
Are mutual funds buying/selling MPS Pharmaa?
There is Insufficient data to gauge this.